Samil Pharmaceutical Co.,Ltd (KRX:000520)
South Korea · Delayed Price · Currency is KRW 6,460.00
+260.00 (4.19%)
Aug 3, 2026, 3:30 PM KST
KRX:000520 Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 138,054 | 205,715 | 279,170 | 96,901 | 108,894 | 106,418 | |
Market Cap Growth | -34.78% | -26.31% | 188.10% | -11.01% | 2.33% | -17.45% |
Enterprise Value | 302,893 | 363,668 | 420,498 | 272,367 | 265,842 | 202,048 |
Last Close Price | 6460.00 | 9690.00 | 13150.00 | 6700.00 | 7800.00 | 7509.09 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 58.25 | - | - |
PS Ratio | 0.66 | 0.98 | 1.27 | 0.49 | 0.61 | 0.79 |
PB Ratio | 1.07 | 1.54 | 1.59 | 0.76 | 0.87 | 1.62 |
P/TBV Ratio | 1.11 | 1.59 | 1.63 | 0.77 | 0.89 | 1.65 |
P/OCF Ratio | 12.50 | 362.07 | 107.79 | 8.25 | 26.22 | 75.11 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.44 | 1.73 | 1.91 | 1.39 | 1.48 | 1.51 |
EV/EBITDA Ratio | - | - | 57.52 | 23.03 | 29.52 | 39.53 |
EV/EBIT Ratio | - | - | 8739.66 | 42.16 | 66.19 | 505.45 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.29 | 1.23 | 0.85 | 1.38 | 1.27 | 1.91 |
Debt / EBITDA Ratio | - | - | 20.53 | 14.87 | 17.68 | 24.55 |
Net Debt / Equity Ratio | 1.28 | 1.18 | 0.82 | 1.37 | 1.25 | 1.68 |
Net Debt / EBITDA Ratio | -9.36 | -10.69 | 19.83 | 14.79 | 17.47 | 21.57 |
Net Debt / FCF Ratio | 186.00 | -22.88 | -52.11 | -14.00 | -3.55 | -3.51 |
Asset Turnover | 0.55 | 0.55 | 0.57 | 0.54 | 0.62 | 0.64 |
Inventory Turnover | 3.73 | 3.83 | 4.13 | 4.27 | 4.59 | 3.53 |
Quick Ratio | 0.23 | 0.23 | 0.38 | 0.22 | 0.27 | 0.38 |
Current Ratio | 0.46 | 0.44 | 0.86 | 0.48 | 0.56 | 0.63 |
Return on Equity (ROE) | -24.71% | -22.41% | -3.70% | 1.31% | -0.03% | -8.27% |
Return on Assets (ROA) | -4.38% | -3.90% | 0.01% | 1.11% | 0.86% | 0.12% |
Return on Invested Capital (ROIC) | -9.22% | -7.82% | 0.01% | 2.21% | -0.05% | 0.25% |
Return on Capital Employed (ROCE) | -12.90% | -12.80% | 0.00% | 3.20% | 1.80% | 0.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -26.38% | -16.85% | -2.02% | 1.72% | -0.03% | -5.02% |
FCF Yield | 0.64% | -3.35% | -1.00% | -12.90% | -40.71% | -29.52% |
Buyback Yield / Dilution | -10.91% | -18.05% | -24.32% | -3.75% | -0.82% | -2.85% |
Total Shareholder Return | -10.91% | -18.05% | -24.32% | -3.75% | -0.82% | -2.85% |